Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by FormerHedgieon May 21, 2024 4:07pm
153 Views
Post# 36050675

MEH Quarter... I wish someone would acquire Biosyent....

MEH Quarter... I wish someone would acquire Biosyent....I just took some time to read the financial statements, MD&A and AIF that were released in conjunction with the quarter.  I guess my net impression was MEH....

The current share price is a pretty fair value for where the company is at.


If we are going to grind along at this pace, I wish that Rene and the complicit board would just arrange an LBO, pay us 10-11x FTM EBTIDA ($10-$11/share) and let us move on.  It has been like watching paint dry for quite a while now.  With >25% of the market cap in cash ($27.7M) and tepid growth but good profitability, he could leverage up the company and take it private.

One new thing I did learn is that we, as shareholders, are funding management's purchase of company shares with loans to themselves that have an annual interest rate of 1% (NOTE 11 / Loans Receivable). These loans have been in place since 2017 and will continue in affect until at least 2027.   I would like to have a 1% loan too, where can I get my loan?  Also, the financial statements refer to "MSLP" but the abbreviation isn't actually spelled out anywhere.

LETS ACTUALLY DO SOMETHING IF WE ARE GOING CONTINUE ON!!!!!





<< Previous
Bullboard Posts
Next >>